Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MART-1 and GP100 Peptides +/- IL-2 in Metastatic Melanoma
NCT00019721Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 1999
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mart-1 antigen and gp100 antigen in melanoma (5 arms), sponsored by National Cancer Institute. Primary endpoint: Efficacy of peptides with or without IL-2. Started Apr 1999; status: completed.
02
Drugs
mart-1 antigengp100 antigen
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00019721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019721.